In addition, it evaluated the sensitivity and specificity of standard surveillance methods—namely ultrasound combined with AFP—and explored the diagnostic performance of PIVKA-II, a biomarker not yet incorporated into routine HCC surveillance protocols in Europe. The gene discussed is AFP; the disease is hepatocellular carcinoma.